VivoSeq
Other

G-CSF

0

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

G-CSF is an early-stage landscape with 0 programs across 1 company. The most active players are Sanofi.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

16

clinical trials

Completed12 · 75%
Unknown status4 · 25%

Clinical Trials

Trial Activity

16 trials

A Phase I PK/PD Study of PEG-MetHuG-CSF (P2203) in Healthy Volunteers
Completed·PPharmaEssentia·Phase 1·NCT06698861·30 enrolled
Influence of G-CSF and EPO on Associative Learning and Motor Skills
Completed·UUniversity Hospital Muenster·Phase 2·NCT00298597·180 enrolled
Intrauterine G-CSF Administration in RIF
Completed·GGurgan Clinic·N/A·NCT03783208·157 enrolled
Pharmacokinetic/Pharmacodynamic (PK/PD) Study Evaluating DA-3031 (PEG-G-CSF) to Filgrastim (Dong-A) in Healthy Volunteers
Completed·DDong-A ST Co., Ltd.·Phase 1·NCT00959777
Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide Regeneration
Completed·CCentre Georges Francois Leclerc·N/A·NCT05296317·97 enrolled
Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant
Completed·WWashington University School of Medicine·Phase 1·NCT01026987·29 enrolled
Evaluation of Pharmacokinetic and Pharmacodynamic Parameters of Filgrastim (G-CSF)Produced by Blausiegel Indústria e Comércio Ltda. Compared to Granulokine Produced by Produtos Roche Químicos e Farmacêuticos S/A.
Completed·—·Phase 1·NCT01549301·128 enrolled
ATRA Plus G-CSF for Mobilization of Hematopoietic Stem and Progenitor Cells
Completed·PPeter MacCallum Cancer Centre, Australia·Phase 1·NCT00400556·6 enrolled
AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF
Completed·Sanofi logoSanofi·Phase 2·NCT00396266·22 enrolled
G-CSF for Granulocyte Donation
Completed·National Institutes of Health Clinical Center (CC)·Phase 1·NCT00001842·16 enrolled
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin
Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00822770·47 enrolled
A Study of Peripheral Blood Progenitor Cells Mobilisation (PBPC) With VTP195183 Plus Granulocyte-Colony Stimulating Factor (G-CSF) Compared to Mobilisation With G-CSF Alone
Completed·PPeter MacCallum Cancer Centre, Australia·Phase 1/2·NCT00234169·30 enrolled
FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML
Unknown status·CCooperative Study Group A for Hematology·Phase 2·NCT00559221·37 enrolled
G-CSF Administration in IVF in a Preferable Preceptive Endometrium Score
Unknown status·—·Phase 2/3·NCT03163862·100 enrolled
A Comparative, Crossover, Pharmacokinetic, Pharmacodynamic and Safety Study of Three Forms of PEG-G-CSF in Normal Healthy Volunteers
Unknown status·—·Phase 1·NCT02205320·192 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)